ARTICLE | Clinical News

Ergomed's PeproStat meets in Phase II for intraoperative surgical bleeding

February 16, 2018 5:25 PM UTC

In October, Ergomed plc (LSE:ERGO) reported top-line data from a Phase II trial to treat intraoperative surgical bleeding in 169 patients undergoing liver/soft tissue, vascular or spinal surgery showing that PeproStat met the primary endpoint of reducing the time to hemostasis vs. a gelatin sponge (p<0.0041). Specifically, PeproStat reduced the time to hemostasis by 1.55 minutes.

On secondary endpoints, PeproStat led to a time to hemostasis of ≤2 minutes in 58.2% of patients vs. 32.7% for the gelatin sponge, a rating of good to excellent from 80.9% of investigators vs. 59.6% for the gelatin sponge, and a rating of easy to very easy to use from 93.5% of investigators. PeproStat was safe with no treatment-related serious adverse events reported...

BCIQ Company Profiles

Ergomed plc